TTTomomi Tadokoro

Tomomi Tadokoro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomomi Tadokoro has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Hideki Taniguchi

    Division of Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    7 shared publications
  • Soichiro Murata

    Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

    4 shared publications
  • Akihiro Mori

    Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

    3 shared publications
  • Satoshi Okamoto

    Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, 3-9, Fuku-ura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan

    3 shared publications
  • Mimoko Kato

    Department of Regenerative Medicine, Yokohama City University School of Medicine, Kanagawa, 236-0004, Japan

    2 shared publications
  • Satoshi Mikami

    Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, 3-9, Fuku-ura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan

    2 shared publications

Latest Publications

  • Open Access

    Chromosome-scale reference genome assembly of an Aokubi Raphanus sativus doubled haploid line

    by Goro Masuda, Akito Hosoi, Kenji Komatsu, Yuki Mitsui, Yuko Arai-Kichise, Asuka Kamio, Rahul Sk, Hiroto Sekitoh, Miho Ozeki, Takashi Matsumoto, et al.

    Radish ( Raphanus sativus L.) exhibits substantial morphological and agronomic diversity, with Aokubi cultivars representing a major lineage in Japanese breeding programs. Although several radish genomes have been published so far, no chromosome-scale reference for the Aokubi lineage exists. Here we present a chromosome-scale genome assembly of an Aokubi doubled haploid line generated using Oxford Nanopore long-read sequencing and Bionano optical genome mapping. PromethION sequencing produced 71.0 Gb of long-read data (N50 = 41.2 kb; 123 × coverage). Hybrid scaffolding with Bionano optical maps, complemented by ntLink long-read scaffolding, anchored the assembly into nine pseudochromosomes, yielding a total size of 476.1 Mb with a scaffold N50 of 52.2 Mb. BUSCO analysis using brassicales_odb12 indicated 99.2% completeness. Telomeric repeats were identified at 17 of 18 chromosome termini, and centromeric regions were identified on all nine pseudochromosomes. Repeat annotation showed 61.5% repetitive content, and BRAKER3 gene prediction produced 40,973 protein-coding genes. This assembly provides a foundational resource for structural variation analysis, functional genomics, and molecular breeding in radish.

  • Open Access

    Propionic Acid Supports the Development of Oocytes Derived from Bovine Early Antral Follicles

    by Takuya Ui, Kota Ushiroshoji, Genya Ito, Tatsuo Noguchi, Tomomi Tadokoro, Koumei Shirasuna, Hisataka Iwata

    The present study investigated the effects of propionic acid (PA) supplementation during the in vitro growth of oocytes derived from bovine early antral follicles (EAFs) on oocyte quality and granulosa cell (GC) characteristics. Oocyte–GC complexes (OGCs) were collected from bovine ovaries and cultured for 14 days in medium supplemented with or without 0.01 mM PA. Oocytes and GCs obtained from large antral follicles were used as in vivo controls. Oocytes cultured with PA exhibited higher nuclear maturation and fertilization rates than those cultured without PA. PA supplementation increased lipid content and ATP levels in both oocytes and GCs and enhanced glucose consumption in OGCs. However, compared with in vivo-grown oocytes, in vitro-grown oocytes showed lower ATP levels, lipid content, mitochondrial membrane potential, and fertilization ability. RNA-seq followed by K-medoids clustering analysis revealed that PA-induced genes in GCs showing expression patterns similar to those in vivo were mainly associated with oxidative phosphorylation, whereas genes showing expression patterns distinct from the in vivo profile were associated with the PI3K–Akt signaling pathway. In conclusion, PA improves the quality of in vitro-grown oocytes and is associated with enhanced energy status in both oocytes and GCs. However, some PA-induced gene expression patterns in GCs differed from those observed in vivo.


  • Open Access

    Placenta-derived factors contribute to human iPSC-liver organoid growth

    by Yoshiki Kuse, Shinya Matsumoto, Syusaku Tsuzuki, Erica Carolina, Takashi Okumura, Toshiharu Kasai, Soichiro Yamabe, Kiyoshi Yamaguchi, Yoichi Furukawa, Tomomi Tadokoro, et al.

    Organoids derived from human induced pluripotent stem cells (hiPSC) are potentially applicable for regenerative medicine. However, the applications have been hampered by limited organoid size and function as a consequence of a lack of progenitor expansion. Here, we report the recapitulation of progenitor expansion in hiPSC-liver organoids based on the analysis of mouse development. Visualization of blood perfusion and oxygen levels in mouse embryos reveals a transient hypoxic environment during hepatoblast expansion, despite active blood flow. During this specific stage, the placenta expresses various growth factors. Human and mouse placenta-liver interaction analysis identifies various placenta-derived factors. Among them, IL1α efficiently induces the growth in hiPSC-liver organoids as well as mouse fetal livers following progenitor expansion under hypoxia. Furthermore, subsequent oxygenation demonstrates that progenitors expanded by IL1α contribute to hiPSC-liver organoid size and function. Taken together, we demonstrate that treatment with the placenta-derived factor under hypoxia is a crucial human organoid culture technique that efficiently induces progenitor expansion.


  • Open Access

    Optimizing cell migration assays: Critical roles of fluorescent labeling and chemoattractant gradients

    by Tomomi Tadokoro, Mimoko Kato, Tatsuya Kobayashi, Hideki Taniguchi


  • Human iPSC–liver organoid transplantation reduces fibrosis through immunomodulation

    by Tomomi Tadokoro, Soichiro Murata, Mimoko Kato, Yasuharu Ueno, Tomonori Tsuchida, Ayumu Okumura, Yoshiki Kuse, Takahiro Konno, Yutaro Uchida, Yuriko Yamakawa, et al.

    Donor organ shortages for transplantation remain a serious global concern, and alternative treatment is in high demand. Fetal cells and tissues have considerable therapeutic potential as, for example, organoid technology that uses human induced pluripotent stem cells (hiPSCs) to generate unlimited human fetal-like cells and tissues. We previously reported the in vivo vascularization of early fetal liver–like hiPSC-derived liver buds (LBs) and subsquent improved survival of recipient mice with subacute liver failure. Here, we show hiPSC–liver organoids (LOs) that recapitulate midgestational fetal liver promote de novo liver generation when grafted onto the surface of host livers in chemical fibrosis models, thereby recovering liver function. We found that fetal liver, a hematopoietic tissue, highly expressed macrophage-recruiting factors and antifibrotic M2 macrophage polarization factors compared with the adult liver, resulting in fibrosis reduction because of CD163 + M2-macrophage polarization. Next, we created midgestational fetal liver–like hiPSC-LOs by fusion of hiPSC-LBs to induce static cell-cell interactions and found that these contained complex structures such as hepatocytes, vasculature, and bile ducts after transplantation. This fusion allowed the generation of a large human tissue suitable for transplantation into immunodeficient rodent models of liver fibrosis. hiPSC-LOs showed superior liver function compared with hiPSC-LBs and improved survival and liver function upon transplantation. In addition, hiPSC-LO transplantation ameliorated chemically induced liver fibrosis, a symptom of liver cirrhosis that leads to organ dysfunction, through immunomodulatory effects, particularly on CD163 + phagocytic M2-macrophage polarization. Together, our results suggest hiPSC-LO transplantation as a promising therapeutic option for liver fibrosis.


  • Open Access

    Dorso-ventral heterogeneity in tracheal basal stem cells

    by Tomomi Tadokoro, Keisuke Tanaka, Shun Osakabe, Mimoko Kato, Hisato Kobayashi, Brigid L. M. Hogan, Hideki Taniguchi

    The tracheal basal cells (BCs) function as stem cells to maintain the epithelium in steady state and repair it after injury. The airway is surrounded by cartilage ventrolaterally and smooth muscle dorsally. Lineage tracing using Krt5-CreER shows dorsal BCs produce more, larger, clones than ventral BCs. Large clones were found between cartilage and smooth muscle where subpopulation of dorsal BCs exists. Three-dimensional organoid culture of BCs demonstrated that dorsal BCs show higher colony forming efficacy to ventral BCs. Gene ontology analysis revealed that genes expressed in dorsal BCs are enriched in wound healing while ventral BCs are enriched in response to external stimulus and immune response. Significantly, ventral BCs express Myostatin, which inhibits the growth of smooth muscle cells, and HGF, which facilitates cartilage repair. The results support the hypothesis that BCs from the dorso-ventral airways have intrinsic molecular and behavioural differences relevant to their in vivo function.


  • Open Access

    A Novel Orthotopic Liver Cancer Model for Creating a Human-like Tumor Microenvironment

    by Rong Qiu, Soichiro Murata, Chao Cheng, Akihiro Mori, Yunzhong Nie, Satoshi Mikami, Shunsuke Hasegawa, Tomomi Tadokoro, Satoshi Okamoto, Hideki Taniguchi

    Hepatocellular carcinoma (HCC) is the most common form of liver cancer. This study aims to develop a new method to generate an HCC mouse model with a human tumor, and imitates the tumor microenvironment (TME) of clinical patients. Here, we have generated functional, three-dimensional sheet-like human HCC organoids in vitro, using luciferase-expressing Huh7 cells, human iPSC-derived endothelial cells (iPSC-EC), and human iPSC-derived mesenchymal cells (iPSC-MC). The HCC organoid, capped by ultra-purified alginate gel, was implanted into the disrupted liver using an ultrasonic homogenizer in the immune-deficient mouse, which improved the survival and engraftment rate. We successfully introduced different types of controllable TME into the model and studied the roles of TME in HCC tumor growth. The results showed the role of the iPSC-EC and iPSC-MC combination, especially the iPSC-MC, in promoting HCC growth. We also demonstrated that liver fibrosis could promote HCC tumor growth. However, it is not affected by non-alcoholic fatty liver disease. Furthermore, the implantation of HCC organoids to humanized mice demonstrated that the immune response is important in slowing down tumor growth at an early stage. In conclusion, we have created an HCC model that is useful for studying HCC development and developing new treatment options in the future.


  • Open Access

    Establishment of Human Leukocyte Antigen-Mismatched Immune Responses after Transplantation of Human Liver Bud in Humanized Mouse Models

    by Akihiro Mori, Soichiro Murata, Nao Tashiro, Tomomi Tadokoro, Satoshi Okamoto, Ryo Otsuka, Haruka Wada, Tomoki Murata, Takeshi Takahashi, Ken-Ichiro Seino, et al.

    Humanized mouse models have contributed significantly to human immunology research. In transplant immunity, human immune cell responses to donor grafts have not been reproduced in a humanized animal model. To elicit human T-cell immune responses, we generated immune-compromised nonobese diabetic/Shi-scid, IL-2RγKO Jic (NOG) with a homozygous expression of human leukocyte antigen (HLA) class I heavy chain (NOG-HLA-A2Tg) mice. After the transplantation of HLA-A2 human hematopoietic stem cells into NOG-HLA-A2Tg, we succeeded in achieving alloimmune responses after the HLA-mismatched human-induced pluripotent stem cell (hiPSC)-derived liver-like tissue transplantation. This immune response was inhibited by administering tacrolimus. In this model, we reproduced allograft rejection after the human iPSC-derived liver-like tissue transplantation. Human tissue transplantation on the humanized mouse liver surface is a good model that can predict T-cell-mediated cellular rejection that may occur when organ transplantation is performed.


  • Open Access

    The Regenerative Effect of Portal Vein Injection of Liver Organoids by Retrorsine/Partial Hepatectomy in Rats

    by Tomonori Tsuchida, Soichiro Murata, Koichiro Matsuki, Akihiro Mori, Megumi Matsuo, Satoshi Mikami, Satoshi Okamoto, Yasuharu Ueno, Tomomi Tadokoro, Yun-Wen Zheng, et al.

    In this study, we reveal that liver organoid transplantation through the portal vein is a safe and effective method for the treatment of chronic liver damage. The liver organoids significantly reconstituted the hepatocytes; hence, the liver was significantly enlarged in this group, compared to the monolayer cell transplantation group in the retrorsine/partial hepatectomy (RS/PH) model. In the liver organoid transplantation group, the bile ducts were located in the donor area and connected to the recipient bile ducts. Thus, the rate of bile reconstruction in the liver was significantly higher compared to that in the monolayer group. By transplanting liver organoids, we saw a level of 70% replacement of the damaged liver. Consequently, in the transplantation group, diminished ductular reaction and a decrease of placental glutathione S-transferase (GST-p) precancerous lesions were observed. After trans-portal injection, the human induced pluripotent stem cell (hiPSC)-derived liver organoids revealed no translocation outside the liver; in contrast, the monolayer cells had spread to the lungs. The hiPSC-derived liver organoids were attached to the liver in the immunodeficient RS/PH rats. This study clearly demonstrates that liver organoid transplantation through the portal vein is a safe and effective method for the treatment of chronic liver damage in rats.